Y-Intercept (HK)
TRDA icon

Y-Intercept (HK)’s Entrada Therapeutics TRDA Stock Holding History

Y-Intercept (HK)’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-34,687
Closed -$255K – 2095
2026
Q2 		$255K Buy
+34,687
New +$333K 0.01% 1508
2023
Q2 		– Sell
-10,188
Closed -$148K – 1724
2023
Q1 		$148K Buy
+10,188
New +$136K 0.02% 1013

Other funds holding TRDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
PWMG
Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Y-Intercept (HK)'s TRDA Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Entrada Therapeutics (TRDA) in Q3 2026, closing a stake of 34,687 shares — an estimated $255K sold.

Y-Intercept (HK) first reported a position in TRDA in Q1 2023 and held it in 2 quarters. The position peaked at $255K in Q2 2026. 11 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Entrada Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 34,687 Entrada Therapeutics shares in Q3 2026, an estimated $255K.
  • Y-Intercept (HK) first reported a position in Entrada Therapeutics in Q1 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Entrada Therapeutics position peaked at $255K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.